Last reviewed · How we verify
Avelumab (MSB0010718C) (avelumab-msb0010718c)
Avelumab is a marketed drug developed by Pfizer Inc. It is used in combination with pembrolizumab and chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for platinum-containing chemotherapy. The drug has undergone 100 trials and has no publications. Its revenue and mechanism of action are not specified. Avelumab is a monoclonal antibody that targets PD-L1, a protein that helps cancer cells evade the immune system. This makes it a key treatment option for patients with certain types of cancer. The commercial significance of avelumab is its ability to provide a new treatment option for patients who have limited alternatives. There are no pipeline developments mentioned for avelumab.
At a glance
| Generic name | avelumab-msb0010718c |
|---|---|
| Sponsor | Pfizer |
| Drug class | Monoclonal antibody |
| Target | PD-L1 |
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Pembrolizumab plus chemotherapy
- Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy
- Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy
- Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy
- Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy
- Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy
- Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy
- Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy
- Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy
- Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy
- Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy
- Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy
- Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy
- Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy
- Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy
- Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy
- Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy
- Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy
- Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy
- Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy
Common side effects
Drug interactions
- CYP1A2 inhibitors
- CYP1A2 inducers
- CYP3A4 inhibitors
- CYP3A4 inducers
- CYP2C19 inhibitors
- CYP2C19 inducers
- CYP2D6 inhibitors
- CYP2D6 inducers
- Warfarin
- Live vaccines
- Immunosuppressants
- Other immunotherapies
Key clinical trials
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Targeted Therapy and Avelumab in Merkel Cell Carcinoma (PHASE1, PHASE2)
- A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy (PHASE2)
- Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy (PHASE1, PHASE2)
- Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study (PHASE3)
- Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial (PHASE2)
- Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies (PHASE1, PHASE2)
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Avelumab (MSB0010718C) CI brief — competitive landscape report
- Avelumab (MSB0010718C) updates RSS · CI watch RSS
- Pfizer portfolio CI